PTC Therapeutics, Inc. (PTCT)
| Market Cap | 5.18B -1.8% |
| Revenue (ttm) | 1.01B -42.8% |
| Net Income | -38.38M |
| EPS | -0.47 |
| Shares Out | 83.46M |
| PE Ratio | n/a |
| Forward PE | 46.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,117,062 |
| Open | 61.07 |
| Previous Close | 61.07 |
| Day's Range | 59.87 - 62.31 |
| 52-Week Range | 58.80 - 90.87 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 97.81 (+57.53%) |
| Earnings Date | Oct 29, 2026 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $97.81, which is an increase of 57.53% from the latest price.
News
PTC Therapeutics price target lowered to $106 from $108 at Raymond James
Raymond James lowered the firm’s price target on PTC Therapeutics (PTCT) to $106 from $108 and keeps an Outperform rating on the shares. Sephience remains a key near-term growth driver,…
PTC Therapeutics reinstated with a Hold at Truist
Truist analyst Joon Lee reinstated coverage of PTC Therapeutics (PTCT) with a Hold rating and $62 price target The firm states that it is skeptical about the long-term growth outlook…
PTC Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, Oct. 29, 2026
WARREN, N.J., Oct. 15, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its third quarter 2026 financial result...
PTC Therapeutics assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of PTC Therapeutics (PTCT) with a Buy rating with a price target of $90, up from $80. The firm states that its Buy thesis…
PTC Therapeutics price target lowered to $75 from $85 at RBC Capital
RBC Capital lowered the firm’s price target on PTC Therapeutics (PTCT) to $75 from $85 and keeps a Sector Perform rating on the shares as part of a broader research…
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept.
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy
– Completion of BLA submission expected in Q4 2026 – WARREN, N.J., Sept. 21, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agre...
PTC Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Sephience’s launch is outperforming prior PKU therapies, driving raised revenue guidance and strong global expansion. Real-world data confirm broad patient benefit, while pipeline programs advance in Friedreich ataxia, Huntington’s, and Fabry disease. Cash position supports continued growth and business development.
PTC Therapeutics upgraded to Outperform from Market Perform at Leerink
Leerink upgraded PTC Therapeutics (PTCT) to Outperform from Market Perform with a price target of $98, up from $70, after assuming coverage of the name. The firm believes Sephience in…
PTC Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
SEPHIENCE's global launch is driving strong commercial growth, with broad patient uptake, high adherence, and sustained expansion into new markets. The pipeline is advancing with promising data in Huntington's disease and innovative RNA splicing programs, while a robust balance sheet supports strategic acquisitions and future profitability.
PTC Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Management highlighted strong financials, broad PKU launch success, and a robust rare disease pipeline. International growth is expected to accelerate from 2026, with strategic pricing and reimbursement efforts underway. Recent acquisitions and disciplined OpEx support sustainable profitability.
PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., Aug. 27, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Wells Fargo 21st Annual Healthcare Confer...
PTC Therapeutics announces new sephience data
PTC Therapeutics (PTCT) announced that multiple sephience scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism Annual Symposium, taking place...
PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile
– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – C...
PTC Therapeutics to acquire ST-920 from Sangamo Therapeutics
PTC Therapeutics (PTCT) announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease – from Sangamo Therapeutics…
PTC Therapeutics price target raised to $109 from $106 at Wells Fargo
Wells Fargo raised the firm’s price target on PTC Therapeutics (PTCT) to $109 from $106 and keeps an Overweight rating on the shares after meeting with management. The firm believes…
PTC Therapeutics price target raised to $122 from $120 at Barclays
Barclays analyst Eliana Merle raised the firm’s price target on PTC Therapeutics (PTCT) to $122 from $120 and keeps an Overweight rating on the shares. The acquisition of ST-920 in…
PTC Therapeutics Transcript: Investor update
Acquisition of ST-920 Fabry gene therapy aims to accelerate revenue growth by leveraging existing rare disease infrastructure. The therapy shows strong clinical differentiation, broad patient applicability, and robust manufacturing, with global regulatory and commercial expansion planned.
PTC Therapeutics Press release: Investor update
PTC Therapeutics issued a press release on August 12, 2026, disclosing material business information to investors.
PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program
– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy ...
PTC Therapeutics price target raised to $96 from $95 at BofA
BofA raised the firm’s price target on PTC Therapeutics (PTCT) to $96 from $95 and keeps a Buy rating on the shares.
PTC Therapeutics price target raised to $104 from $93 at Morgan Stanley
Morgan Stanley raised the firm’s price target on PTC Therapeutics (PTCT) to $104 from $93 and keeps an Overweight rating on the shares.
PTC Therapeutics price target raised to $106 from $93 at Wells Fargo
Wells Fargo raised the firm’s price target on PTC Therapeutics (PTCT) to $106 from $93 and keeps an Overweight rating on the shares. The firm notes Sephience came in near…
PTC Therapeutics Earnings Call Transcript: Q2 2026
Record Q2 revenue and strong Sephience launch drove raised 2026 guidance, with global expansion and high adherence rates supporting confidence in multi-billion dollar opportunity. Pipeline progress and robust cash position further strengthen outlook.
PTC Therapeutics Earnings release: Q2 2026
PTC Therapeutics released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.